The pharmacokinetics of nifurtimox in chronic renal failure
The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 1992-06, Vol.42 (6), p.671-673 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 673 |
|---|---|
| container_issue | 6 |
| container_start_page | 671 |
| container_title | European journal of clinical pharmacology |
| container_volume | 42 |
| creator | GONZALEZ-MARTIN, G THAMBO, S PAULOS, C VASQUEZ, I PAREDES, J |
| description | The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects. |
| doi_str_mv | 10.1007/BF00265935 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_pascalfrancis_primary_4538815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73058377</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-f4fac57682977a569c9cf113278f73034f2f6b120031c18859baef622ce3f2963</originalsourceid><addsrcrecordid>eNpFkEtLAzEURoMotVY37oUsxIUwmptMXriqxapQcFPXQxoTGp2Z1GQG9N87pcWu7uI7HC4HoUsgd0CIvH-cE0IF14wfoTGUjBZASjhGY0IYFEJLcorOcv4kBLgmbIRGICjTAGP0sFw7vFmb1Bgbv0LrumAzjh63wfepC038waHFdp1iGyxOrjU19ibUfXLn6MSbOruL_Z2g9_nTcvZSLN6eX2fTRWEZQFf40hvLpVBUS2m40FZbD8CoVF4ywkpPvVgB3T5rQSmuV8Z5Qal1zFMt2ATd7LybFL97l7uqCdm6ujati32uBglXTMoBvN2BNsWck_PVJoXGpN8KSLUtVR1KDfDV3tqvGvdxQHdphv16v5tsTe2TaW3I_1jJmVLA2R8oBm4G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73058377</pqid></control><display><type>article</type><title>The pharmacokinetics of nifurtimox in chronic renal failure</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>GONZALEZ-MARTIN, G ; THAMBO, S ; PAULOS, C ; VASQUEZ, I ; PAREDES, J</creator><creatorcontrib>GONZALEZ-MARTIN, G ; THAMBO, S ; PAULOS, C ; VASQUEZ, I ; PAREDES, J</creatorcontrib><description>The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00265935</identifier><identifier>PMID: 1623911</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiparasitic agents ; Biological and medical sciences ; Female ; Humans ; Kidney Failure, Chronic - metabolism ; Male ; Medical sciences ; Metabolic Clearance Rate ; Middle Aged ; Nifurtimox - blood ; Nifurtimox - pharmacokinetics ; Pharmacology. Drug treatments ; Renal Dialysis</subject><ispartof>European journal of clinical pharmacology, 1992-06, Vol.42 (6), p.671-673</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-f4fac57682977a569c9cf113278f73034f2f6b120031c18859baef622ce3f2963</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4538815$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1623911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GONZALEZ-MARTIN, G</creatorcontrib><creatorcontrib>THAMBO, S</creatorcontrib><creatorcontrib>PAULOS, C</creatorcontrib><creatorcontrib>VASQUEZ, I</creatorcontrib><creatorcontrib>PAREDES, J</creatorcontrib><title>The pharmacokinetics of nifurtimox in chronic renal failure</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects.</description><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Middle Aged</subject><subject>Nifurtimox - blood</subject><subject>Nifurtimox - pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Renal Dialysis</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLAzEURoMotVY37oUsxIUwmptMXriqxapQcFPXQxoTGp2Z1GQG9N87pcWu7uI7HC4HoUsgd0CIvH-cE0IF14wfoTGUjBZASjhGY0IYFEJLcorOcv4kBLgmbIRGICjTAGP0sFw7vFmb1Bgbv0LrumAzjh63wfepC038waHFdp1iGyxOrjU19ibUfXLn6MSbOruL_Z2g9_nTcvZSLN6eX2fTRWEZQFf40hvLpVBUS2m40FZbD8CoVF4ywkpPvVgB3T5rQSmuV8Z5Qal1zFMt2ATd7LybFL97l7uqCdm6ujati32uBglXTMoBvN2BNsWck_PVJoXGpN8KSLUtVR1KDfDV3tqvGvdxQHdphv16v5tsTe2TaW3I_1jJmVLA2R8oBm4G</recordid><startdate>19920601</startdate><enddate>19920601</enddate><creator>GONZALEZ-MARTIN, G</creator><creator>THAMBO, S</creator><creator>PAULOS, C</creator><creator>VASQUEZ, I</creator><creator>PAREDES, J</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920601</creationdate><title>The pharmacokinetics of nifurtimox in chronic renal failure</title><author>GONZALEZ-MARTIN, G ; THAMBO, S ; PAULOS, C ; VASQUEZ, I ; PAREDES, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-f4fac57682977a569c9cf113278f73034f2f6b120031c18859baef622ce3f2963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Middle Aged</topic><topic>Nifurtimox - blood</topic><topic>Nifurtimox - pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Renal Dialysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GONZALEZ-MARTIN, G</creatorcontrib><creatorcontrib>THAMBO, S</creatorcontrib><creatorcontrib>PAULOS, C</creatorcontrib><creatorcontrib>VASQUEZ, I</creatorcontrib><creatorcontrib>PAREDES, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GONZALEZ-MARTIN, G</au><au>THAMBO, S</au><au>PAULOS, C</au><au>VASQUEZ, I</au><au>PAREDES, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The pharmacokinetics of nifurtimox in chronic renal failure</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1992-06-01</date><risdate>1992</risdate><volume>42</volume><issue>6</issue><spage>671</spage><epage>673</epage><pages>671-673</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>1623911</pmid><doi>10.1007/BF00265935</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 1992-06, Vol.42 (6), p.671-673 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_4538815 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiparasitic agents Biological and medical sciences Female Humans Kidney Failure, Chronic - metabolism Male Medical sciences Metabolic Clearance Rate Middle Aged Nifurtimox - blood Nifurtimox - pharmacokinetics Pharmacology. Drug treatments Renal Dialysis |
| title | The pharmacokinetics of nifurtimox in chronic renal failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A57%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20pharmacokinetics%20of%20nifurtimox%20in%20chronic%20renal%20failure&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=GONZALEZ-MARTIN,%20G&rft.date=1992-06-01&rft.volume=42&rft.issue=6&rft.spage=671&rft.epage=673&rft.pages=671-673&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00265935&rft_dat=%3Cproquest_cross%3E73058377%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73058377&rft_id=info:pmid/1623911&rfr_iscdi=true |